Schmelter, C.; Fomo, K.N.; Perumal, N.; Manicam, C.; Bell, K.; Pfeiffer, N.; Grus, F.H.
Synthetic Polyclonal-Derived CDR Peptides as an Innovative Strategy in Glaucoma Therapy. J. Clin. Med. 2019, 8, 1222.
https://doi.org/10.3390/jcm8081222
AMA Style
Schmelter C, Fomo KN, Perumal N, Manicam C, Bell K, Pfeiffer N, Grus FH.
Synthetic Polyclonal-Derived CDR Peptides as an Innovative Strategy in Glaucoma Therapy. Journal of Clinical Medicine. 2019; 8(8):1222.
https://doi.org/10.3390/jcm8081222
Chicago/Turabian Style
Schmelter, Carsten, Kristian Nzogang Fomo, Natarajan Perumal, Caroline Manicam, Katharina Bell, Norbert Pfeiffer, and Franz H. Grus.
2019. "Synthetic Polyclonal-Derived CDR Peptides as an Innovative Strategy in Glaucoma Therapy" Journal of Clinical Medicine 8, no. 8: 1222.
https://doi.org/10.3390/jcm8081222
APA Style
Schmelter, C., Fomo, K. N., Perumal, N., Manicam, C., Bell, K., Pfeiffer, N., & Grus, F. H.
(2019). Synthetic Polyclonal-Derived CDR Peptides as an Innovative Strategy in Glaucoma Therapy. Journal of Clinical Medicine, 8(8), 1222.
https://doi.org/10.3390/jcm8081222